false
0001178697
0001178697
2025-09-29
2025-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d)
of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) September 29, 2025
Sonim
Technologies, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38907 |
|
94-3336783 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
4445
Eastgate Mall, Suite 200,
San
Diego, CA 92121
(Address
of principal executive offices, including Zip Code)
(650)
378-8100
(Registrant’s
telephone number, including area code)
Not
applicable.
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
SONM |
|
The
Nasdaq Stock Market LLC
(Nasdaq
Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
September 29, 2025, Sonim Technologies, Inc. (the “Company”) entered into a ChEF purchase agreement
(the “Purchase Agreement”) and registration rights agreement (the “Registration Rights Agreement”), each with
Chardan Capital Markets LLC (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Facility”).
Pursuant
to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $500,000,000
in aggregate gross purchase price of newly issued shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), and (ii) the Exchange Cap (as defined below), subject to certain conditions and limitations set forth in the Purchase
Agreement. The Company is under no obligation to sell any securities to Chardan under the Purchase Agreement.
Facility
While
there are distinct differences, the Facility is structured similarly to a traditional “at-the-market” equity facility, insofar
as it allows the Company to raise primary equity capital on a periodic basis outside the context of a traditional underwritten follow-on
offering. From and after the Commencement (as defined below), sales of Common Stock to Chardan under the Purchase Agreement, and the
timing of any sales, will be determined by the Company from time to time in its sole discretion and will depend on a variety of factors
including, among other things, market conditions, the trading price of the Common Stock and determinations by the Company regarding the
use of proceeds of such Common Stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with,
and prices at, which the shares of Common Stock are sold to Chardan. If and when the Company becomes eligible for use of a Registration
Statement on Form S-3 without limitations on the amount of securities that may be sold under such Registration Statement on Form S-3
pursuant General Instruction I.B.6., the Company and Chardan agreed to enter into an equity distribution or sales agreement providing
for “at-the-market” sales of Common Stock through Chardan (or its designee) as the Company’s sole placement agent on
customary terms.
Mechanics
of Sales under the Facility
Upon
the satisfaction of the conditions to Chardan’s purchase obligation set forth in the Purchase Agreement (the “Commencement”
and the date of initial satisfaction of all of such conditions, the “Commencement Date”), including that a registration statement
registering the resale by Chardan of shares of Common Stock issued to it by the Company under the Purchase Agreement (the “Initial
Resale Registration Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), which the Company
agreed to file with the Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement, is
declared effective by the SEC (the date of such effectiveness, the “Effective Date”) and a final prospectus relating thereto
is filed with the SEC, the Company will have the right, but not the obligation, from time to time at the Company’s sole discretion
over the term of the Purchase Agreement, to direct Chardan to purchase up to an amount of shares of Common Stock (the “VWAP Purchase
Share Amount”) not to exceed certain limitations set forth in the Purchase Agreement (each, a “VWAP Purchase”) by delivering
a written notice (a “VWAP Purchase Notice”) to Chardan after 6:00 a.m., New York City time, but prior to 9:00 a.m., New York
City time on any trading day (the “Purchase Date”), so long as all shares of Common Stock subject to all prior VWAP Purchases
and Intraday VWAP Purchases (as defined below) theretofore required to have been received by Chardan have been received by Chardan in
accordance with the Purchase Agreement and certain other conditions have been satisfied. The purchase price of the shares of Common Stock
that the Company elects to sell to Chardan pursuant to the Purchase Agreement will be determined by reference to the volume weighted
average price of the Common Stock (“VWAP”) during the applicable Purchase Date on which the Company has timely delivered
a VWAP Purchase Notice (and/or Intraday VWAP Purchase Notice (as defined below), as applicable), less a fixed 3.5% discount to such VWAP.
In
addition to the regular VWAP Purchases described above, after the Commencement, the Company will also have the right, but not the obligation,
subject to the continued satisfaction of the conditions set forth in the Purchase Agreement, from time to time at the Company’s
sole discretion over the 36-month period from and after the Effective Date, to offer to Chardan the right to or, in certain circumstances,
to direct Chardan, to purchase, on any trading day, including the same Purchase Date on which a regular VWAP Purchase is effected, up
to an amount of shares of Common Stock (the “Intraday VWAP Purchase Share Amount”) not to exceed certain limitations set
forth in the Purchase Agreement that are similar to those that apply to a regular VWAP Purchase (each, an “Intraday VWAP Purchase”),
by delivering a written notice (each, an “Intraday VWAP Purchase Notice”) to Chardan prior to 3:00 p.m., New York City time,
on such Purchase Date.
The
Purchase Agreement provides that the number of shares of Common Stock issuable pursuant to any VWAP Purchase Notice (and, if applicable,
the number of shares of Common Stock issuable pursuant to any Intraday VWAP Purchase Notice delivered on the same Purchase Date that
such VWAP Purchase Notice is delivered) shall not, without Chardan’s express written agreement exceed the lesser of: (i) the number
of shares of Common Stock which, when aggregated with all other shares of Common Stock then beneficially owned by Chardan and its affiliates,
would exceed the Beneficial Ownership Limitation (as defined below), (ii) the number of shares of Common Stock which would cause the
total aggregate purchase price to be paid by Chardan in any VWAP Purchase together with, if applicable, all Intraday VWAP Purchases,
made on one Purchase Date, to exceed $1.0 million, (iii) the number of shares of Common Stock that equals 20% of the total number (or
volume) of shares of Common Stock traded on the Nasdaq Capital Market (“Nasdaq”) (or a successor Principal Market (as defined
in the Purchase Agreement)) during the applicable purchase period on such Purchase Date, and (iv) the VWAP Purchase Share Amount (for
a VWAP Purchase) or the Intraday VWAP Purchase Share Amount (for an Intraday VWAP Purchase).
Under
the applicable rules and regulations of Nasdaq, in no event may the Company issue to Chardan under the Purchase Agreement more than 2,066,747
shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to
the execution of the Purchase Agreement (the “Exchange Cap”), unless the Company’s stockholders have approved the issuance
of Common Stock pursuant to the Purchase Agreement in excess of the Exchange Cap in accordance with the applicable rules and regulations
of Nasdaq or such approval is not required in accordance with the applicable rules and regulations of Nasdaq or otherwise because the average price of all applicable sales of our Common Stock to Chardan pursuant to the Purchase Agreement
equals or exceeds $0.6277 per share, which represents the “Nasdaq Minimum Price” as of the date of the execution of the Purchase
Agreement. The
Exchange Cap is not applicable to issuances and sales of Common Stock pursuant to VWAP Purchases and Intraday VWAP Purchases that the
Company may effect pursuant to the Purchase Agreement to the extent such shares of Common Stock are sold in such VWAP Purchases or Intraday
VWAP Purchases (as applicable) at a price equal to or in excess of the applicable “minimum price” (as defined in Nasdaq Listing
Rule 5635(d)) of the Common Stock, calculated at the time such VWAP Purchases or Intraday VWAP Purchases (as applicable) are effected
by the Company under the Purchase Agreement, if any, as adjusted as necessary for compliance with the rules of Nasdaq to take into account
certain legal fees and expenses payable and/or reimbursable by the Company to Chardan. Moreover, the Company may not issue or sell any
shares of Common Stock to Chardan under the Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially
owned by Chardan and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and Rule 13d-3 promulgated thereunder), would result in Chardan beneficially owning more than 4.99% of the
outstanding shares of Common Stock (the “Beneficial Ownership Limitation”).
Other
Terms and Conditions of the Purchase Agreement and Registration Rights Agreement
There
are no restrictions on future financings, and no rights of first refusal, participation rights, penalties, or liquidated damages in the
Purchase Agreement or Registration Rights Agreement, as applicable, other than a prohibition on entering (with certain limited exceptions)
into a Specified Transaction (as defined in the Purchase Agreement), as further described in the Purchase Agreement. At no time prior
to the date of the Purchase Agreement has Chardan engaged in or effected, in any manner whatsoever, directly or indirectly for its own
principal account, any (i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the
Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock that remains in effect
as of the date of the Purchase Agreement.
Each
of the Purchase Agreement and the Registration Rights Agreement contains customary representations, warranties, conditions and indemnification
obligations of the parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of
such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to limitations
agreed upon by the contracting parties.
The
Purchase Agreement will automatically terminate on the earliest to occur of (i) the 36-month anniversary of the Effective Date of the
Initial Resale Registration Statement (such term being subject to extension by the parties to the Purchase Agreement), (ii) the date
on which Chardan shall have purchased $500,000,000 of shares of Common Stock pursuant to the Purchase Agreement, (iii) the date on which
the Common Stock shall have failed to be listed or quoted on Nasdaq or a successor Principal Market, and (iv) the commencement of certain
bankruptcy proceedings or similar transactions with respect to the Company or all or substantially all of its property.
The
Company has the right to terminate the Purchase Agreement at any time after Commencement, at no cost or penalty, upon ten (10) trading
days’ prior written notice to Chardan. Chardan also has the right to terminate the Purchase Agreement upon ten (10) trading days’
prior written notice to the Company, but only upon the occurrence of certain customary events as listed in the Purchase Agreement. Neither
the Company nor Chardan may assign or transfer its rights and obligations under the Purchase Agreement or the Registration Rights Agreement.
The
Company will also reimburse Chardan up to $125,000 for fees and disbursements of Chardan’s legal counsel in connection with the
entry into the transaction documents and the review of the Initial Resale Registration Statement and additional fees and disbursements
of Chardan’s legal counsel not to exceed $25,000 for each fiscal quarter, in connection with Chardan’s ongoing due diligence
and review of any registration statements and deliverables pursuant to the Purchase Agreement.
The
foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified
in their entirety by reference to, and incorporate herein by reference, the full text of the Purchase Agreement and the Registration
Rights Agreement, which are filed herewith as Exhibit 10.1 and Exhibit 10.2, respectively.
This
Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there
be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.
Use
of Proceeds
The
Company expects to use a minimum of thirty-three percent (33%) of proceeds from any sales under the Purchase Agreement for pre-payment
of the promissory note in the original principal amount of $2,755,000 issued by the Company to Streeterville Capital, LLC on July 11,
2025, pursuant to a note purchase agreement, until and unless such note is repaid. The Company intends to use any remaining proceeds
for operations, to support the overall business strategy, for working capital, and general corporate purposes.
| Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits.
Exhibit
Number |
|
Description |
| |
|
| 10.1 |
|
ChEF Purchase Agreement, dated as of September 29, 2025, by and between Sonim Technologies, Inc. and Chardan Capital Markets LLC. |
| |
|
| 10.2 |
|
Registration Rights Agreement dated as of September 29, 2025, by and between Sonim Technologies, Inc. and Chardan Capital Markets LLC. |
| |
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SONIM
TECHNOLOGIES, INC. |
| |
|
|
| Date:
September 29, 2025 |
By: |
/s/
Clay Crolius |
| |
Name: |
Clay
Crolius |
| |
Title: |
Chief
Financial Officer |
